231 related articles for article (PubMed ID: 18359227)
1. N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1).
Jetter MC; McNally JJ; Youngman MA; McDonnell ME; Dubin AE; Nasser N; Zhang SP; Codd EE; Colburn RW; Stone DR; Brandt MR; Flores CM; Dax SL
Bioorg Med Chem Lett; 2008 Apr; 18(8):2730-4. PubMed ID: 18359227
[TBL] [Abstract][Full Text] [Related]
2. N-Tetrahydroquinolinyl, N-quinolinyl and N-isoquinolinyl biaryl carboxamides as antagonists of TRPV1.
Westaway SM; Chung YK; Davis JB; Holland V; Jerman JC; Medhurst SJ; Rami HK; Stemp G; Stevens AJ; Thompson M; Winborn KY; Wright J
Bioorg Med Chem Lett; 2006 Sep; 16(17):4533-6. PubMed ID: 16806913
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of benzamide derivatives as TRPV1 antagonists.
Shishido Y; Jinno M; Ikeda T; Ito F; Sudo M; Makita N; Ohta A; Iki-Taki A; Ohmi T; Kanai Y; Tamura T; Shimojo M
Bioorg Med Chem Lett; 2008 Feb; 18(3):1072-8. PubMed ID: 18155908
[TBL] [Abstract][Full Text] [Related]
4. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.
Lehto SG; Tamir R; Deng H; Klionsky L; Kuang R; Le A; Lee D; Louis JC; Magal E; Manning BH; Rubino J; Surapaneni S; Tamayo N; Wang T; Wang J; Wang J; Wang W; Youngblood B; Zhang M; Zhu D; Norman MH; Gavva NR
J Pharmacol Exp Ther; 2008 Jul; 326(1):218-29. PubMed ID: 18420600
[TBL] [Abstract][Full Text] [Related]
5. Proton activation does not alter antagonist interaction with the capsaicin-binding pocket of TRPV1.
Gavva NR; Tamir R; Klionsky L; Norman MH; Louis JC; Wild KD; Treanor JJ
Mol Pharmacol; 2005 Dec; 68(6):1524-33. PubMed ID: 16135784
[TBL] [Abstract][Full Text] [Related]
6. [3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand for the human transient receptor potential vanilloid-1 (TRPV1) receptor.
Bianchi BR; El Kouhen R; Neelands TR; Lee CH; Gomtsyan A; Raja SN; Vaidyanathan SN; Surber B; McDonald HA; Surowy CS; Faltynek CR; Moreland RB; Jarvis MF; Puttfarcken PS
J Pharmacol Exp Ther; 2007 Oct; 323(1):285-93. PubMed ID: 17660385
[TBL] [Abstract][Full Text] [Related]
7. Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles.
Ognyanov VI; Balan C; Bannon AW; Bo Y; Dominguez C; Fotsch C; Gore VK; Klionsky L; Ma VV; Qian YX; Tamir R; Wang X; Xi N; Xu S; Zhu D; Gavva NR; Treanor JJ; Norman MH
J Med Chem; 2006 Jun; 49(12):3719-42. PubMed ID: 16759115
[TBL] [Abstract][Full Text] [Related]
8. Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate.
Doherty EM; Fotsch C; Bannon AW; Bo Y; Chen N; Dominguez C; Falsey J; Gavva NR; Katon J; Nixey T; Ognyanov VI; Pettus L; Rzasa RM; Stec M; Surapaneni S; Tamir R; Zhu J; Treanor JJ; Norman MH
J Med Chem; 2007 Jul; 50(15):3515-27. PubMed ID: 17585750
[TBL] [Abstract][Full Text] [Related]
9. Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides.
Norman MH; Zhu J; Fotsch C; Bo Y; Chen N; Chakrabarti P; Doherty EM; Gavva NR; Nishimura N; Nixey T; Ognyanov VI; Rzasa RM; Stec M; Surapaneni S; Tamir R; Viswanadhan VN; Treanor JJ
J Med Chem; 2007 Jul; 50(15):3497-514. PubMed ID: 17585749
[TBL] [Abstract][Full Text] [Related]
10. Identification and synthesis of 2,7-diamino-thiazolo[5,4-d]pyrimidine derivatives as TRPV1 antagonists.
Lebsack AD; Branstetter BJ; Hack MD; Xiao W; Peterson ML; Nasser N; Maher MP; Ao H; Bhattacharya A; Kansagara M; Scott BP; Luo L; Rynberg R; Rizzolio M; Chaplan SR; Wickenden AD; Guy Breitenbucher J
Bioorg Med Chem Lett; 2009 Jan; 19(1):40-6. PubMed ID: 19038548
[TBL] [Abstract][Full Text] [Related]
11. Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties.
Wang HL; Katon J; Balan C; Bannon AW; Bernard C; Doherty EM; Dominguez C; Gavva NR; Gore V; Ma V; Nishimura N; Surapaneni S; Tang P; Tamir R; Thiel O; Treanor JJ; Norman MH
J Med Chem; 2007 Jul; 50(15):3528-39. PubMed ID: 17585751
[TBL] [Abstract][Full Text] [Related]
12. Biarylcarboxybenzamide derivatives as potent vanilloid receptor (VR1) antagonistic ligands.
Park HG; Choi JY; Kim MH; Choi SH; Park MK; Lee J; Suh YG; Cho H; Oh U; Kim HD; Joo YH; Shin SS; Kim JK; Jeong YS; Koh HJ; Park YH; Jew SS
Bioorg Med Chem Lett; 2005 Feb; 15(3):631-4. PubMed ID: 15664827
[TBL] [Abstract][Full Text] [Related]
13. (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo.
Surowy CS; Neelands TR; Bianchi BR; McGaraughty S; El Kouhen R; Han P; Chu KL; McDonald HA; Vos M; Niforatos W; Bayburt EK; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
J Pharmacol Exp Ther; 2008 Sep; 326(3):879-88. PubMed ID: 18515644
[TBL] [Abstract][Full Text] [Related]
14. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo.
Lindsley CW; Wisnoski DD; Leister WH; O'brien JA; Lemaire W; Williams DL; Burno M; Sur C; Kinney GG; Pettibone DJ; Tiller PR; Smith S; Duggan ME; Hartman GD; Conn PJ; Huff JR
J Med Chem; 2004 Nov; 47(24):5825-8. PubMed ID: 15537338
[TBL] [Abstract][Full Text] [Related]
15. 6,6-Fused heterocyclic ureas as highly potent TRPV1 antagonists.
Sun W; Kim HS; Lee S; Jung A; Kim SE; Ann J; Yoon S; Choi S; Lee JH; Blumberg PM; Frank-Foltyn R; Bahrenberg G; Schiene K; Stockhausen H; Christoph T; Frormann S; Lee J
Bioorg Med Chem Lett; 2015 Feb; 25(4):803-6. PubMed ID: 25597011
[TBL] [Abstract][Full Text] [Related]
16. Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.
Voight EA; Gomtsyan AR; Daanen JF; Perner RJ; Schmidt RG; Bayburt EK; DiDomenico S; McDonald HA; Puttfarcken PS; Chen J; Neelands TR; Bianchi BR; Han P; Reilly RM; Franklin PH; Segreti JA; Nelson RA; Su Z; King AJ; Polakowski JS; Baker SJ; Gauvin DM; Lewis LR; Mikusa JP; Joshi SK; Faltynek CR; Kym PR; Kort ME
J Med Chem; 2014 Sep; 57(17):7412-24. PubMed ID: 25100568
[TBL] [Abstract][Full Text] [Related]
17. Heteroaryl beta-tetralin ureas as novel antagonists of human TRPV1.
Jetter MC; Youngman MA; McNally JJ; McDonnell ME; Zhang SP; Dubin AE; Nasser N; Codd EE; Flores CM; Dax SL
Bioorg Med Chem Lett; 2007 Nov; 17(22):6160-3. PubMed ID: 17892935
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of (3S)-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-N-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide (JTS-653), a novel transient receptor potential vanilloid 1 antagonist.
Kitagawa Y; Miyai A; Usui K; Hamada Y; Deai K; Wada M; Koga Y; Sakata M; Hayashi M; Tominaga M; Matsushita M
J Pharmacol Exp Ther; 2012 Aug; 342(2):520-8. PubMed ID: 22588258
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of thiazole carboxamides as vanilloid receptor 1 (TRPV1) antagonists.
Xi N; Bo Y; Doherty EM; Fotsch C; Gavva NR; Han N; Hungate RW; Klionsky L; Liu Q; Tamir R; Xu S; Treanor JJ; Norman MH
Bioorg Med Chem Lett; 2005 Dec; 15(23):5211-7. PubMed ID: 16203144
[TBL] [Abstract][Full Text] [Related]
20. False positives in a reporter gene assay: identification and synthesis of substituted N-pyridin-2-ylbenzamides as competitive inhibitors of firefly luciferase.
Heitman LH; van Veldhoven JP; Zweemer AM; Ye K; Brussee J; IJzerman AP
J Med Chem; 2008 Aug; 51(15):4724-9. PubMed ID: 18646744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
